Furthermore, these findings may be applied going forward in clinical trial development for RA prevention to identify individuals who are at particularly high-risk for imminent onset of clinical IA/RA – and indeed several existing clinical prevention trials have as inclusion criteria either high-positive ACPA levels, or positivity for ACPA plus combinations of RF isotypes (7–9). This evidence concerns the gene PRTN3 and rheumatoid arthritis.